Replies to post #1815 on Idenix Pharmaceuticals (IDIX)

[rkrw]

Semantics. They're working on it :-)

<<Ron Renaud, in reply to a question about the relationship with NVS, said: “At this point, no change.”

Hmm... if no change were being contemplated, why would he add the at this point disclaimer?<<<